{"id":"allocupreide-sodium","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"unknown","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T16:30:40.096197","allNames":"ebesal","offLabel":[],"synonyms":["allocupreide sodium","allocupreide","cupralene","cupralyl sodium","ebesal"],"timeline":[],"brandName":"Ebesal","ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"Imagine your body's cells have locks on them, and Ebesal has a key that fits into one of those locks. When Ebesal binds to its target, it helps to unlock the cell's normal function, which can help to treat certain conditions. This process is like a key turning in a lock, allowing the cell to work properly again.","oneSentence":"Ebesal works by binding to a specific target, modulating its activity to produce a therapeutic effect.","technicalDetail":"Allocupreide sodium is a copper-based compound that acts as a chelator, binding to its target through a copper ion-mediated interaction, thereby modulating its activity and producing a therapeutic effect."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3665","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=allocupreide sodium","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:37:56.318115","biosimilars":[],"competitors":[],"genericName":"allocupreide sodium","indications":{"approved":[],"offLabel":[],"pipeline":[]},"_fixedFields":["pubmed(452611)"],"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"WKG854RBET","INN_ID":"979","UMLSCUI":"C2697991","PUBCHEM_CID":"23697817"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":452611,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 30","pmid":"41906987","title":"Difluorocarbene-Promoted Regioselective Ring-Opening of Benzimidazoles.","journal":"Organic letters"},{"date":"2026 Apr","pmid":"41906918","title":"Electroactive Dual-Drug Hydrogel-PLA Conduit for Nerve Regeneration.","journal":"Journal of biomedical materials research. Part B, Applied biomaterials"},{"date":"2026 Mar 30","pmid":"41906911","title":"Oxygen concentration measurement in 3D cell culture using multifocal optical projection microscopy.","journal":"Analytical methods : advancing methods and applications"},{"date":"2026 Mar 30","pmid":"41906877","title":"Dietary Sodium-Regulated Plasma SVEP1 and Inverse Salt Sensitivity.","journal":"Hypertension (Dallas, Tex. : 1979)"},{"date":"2026 Mar 30","pmid":"41906860","title":"A new flavonoid isolated from the roots of Rumex crispus L. with anti-NAFLD activity.","journal":"Natural product research"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Ebesal is a small molecule with the synonyms E250, INS-250, INS NO.250, NATRII NITRIS, NATRUM NITROSUM, and NITROUS ACID SODA.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}